Children playing with their dogs Children playing with their dogs

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping. Accelerated approval is based on an increase in dystrophin. There is an ongoing study to confirm the clinical benefit of VILTEPSO.

If you are a
HEALTHCARE PROVIDER
who treats patients with DMD

LEARN MORE

If you are a
PATIENT or a CAREGIVER
of a child with DMD

DISCOVER VILTEPSO

If you are
LOOKING FOR SUPPORT
and RESOURCES

If you are LOOKING FOR
SUPPORT and RESOURCES

GET HELPFUL INFORMATION

Providing personalized access support and customized resources

With NS Support, NS Pharma is fully committed to providing ongoing support to patients, their caregivers, and healthcare professionals who treat patients with DMD.

LEARN MORE ABOUT NS SUPPORT
Prescribing Information
News Release
Stay Informed
Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

For more information about VILTEPSO, see full Prescribing Information.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.